I would have thought so ... that was last week. Believe it has to do with a concept called 'corporate governance. - the definition of which is well-understood by most BODs
that's always you're stupid cad answer, melikes, but you intentionally always circumvent the real issue at hand. If you've never bought a single share I suppose you can keep playing that line. Revs need to grow some 20-fold to pay just the basic bills ... probably not going to happen in the next two or three qtrs. is it
may be but the problem with your analysis is that is likely still years away ... far from the 'reality' and out of reach with the cash issue at hand
Do like Germany, but revenues have been building at a trickle. To use your own words, can DCTH afford to wait forever, with only a couple qtrs operating revs left in the bank? Obviously not. If they had some $30-$40 mil in the bank as we speak then I'd agree:
I don't see how selling 1.5 million shrs at current levels does anything really to support the Co. What is that, 2 wks operating expenses?
On another point, will Dcth share interim results of HCC with FDA before their release?
Again, I would agree with you if Delcath had considerably more cash on hand than for only two or three more quarters going forward. Europe, though promising, seems will take a good deal more time than that to mature in a meaningful way - more time I believe than can be afforded. That's leads us back to where it all began -- to the FDA. (I think the company increasingly is providing an answer for an important unmet need ... the agency should come back around, take a hard look and accelerate).
I think that the Germany/EU argument for Chemostat and G2 is plausible and could make a lot of sense if, if Delcath already some $30-$40 million in the bank, and not just enough cash on hand to carry it through part of the year. Therein lies the fixation on some development or breakthrough with the FDA as providing some new opportunity - at least for the 'current' stockholders in the company. But I think all understand this.
Huh? wow, what a smartarse jerk ... sure hope dcth has some smarter flaks than you working the boards
Nice thought -- just how many quarters are you anticipating it will take for reimbursement in Germany to be able to cover the company's operating costs ($4 million quarterly).
I'm taking the unloved and contrarian view - that the bottom for Iron ore is pretty much in, has already been hit or within a dollar or two, and then firming from there in the weeks ahead coming out of Chinese New Year.
Hi Akon, you've been here longer than most it seems, so you must have some latent interest, still, in the company's offerings. Wondering what it might take now to shift your interest from a trade to an investment?
Vale has some headwinds to pass through, as does the whole industry, but for Vale the depreciating brazilian real is not one of them. It pays it bills in local currency, but sells its ore and gets paid in USD ... an exchange that works to its benefit.
hey Jonas ... are you the same Jonas that was ringing church bells down on the Bowery Thurs. night? twas you, wasn't it?
The price action that follows is almost always the big reduction we witnessed today. No doubt the advisers or institutions working with them were big shorts, the only thing we can be reasonably sure of.